Resistance to targeted therapy in renal-cell carcinoma - Abstract - UroToday Print
UroToday... mammalian target of rapamycin (mtor), has produced robust clinical effects and revolutionised the treatment of metastatic renal-cell carcinoma (RCC).

... read more